The Isfahan cohort study: rationale, methods and main findings.
about
Comparison of competing risks models based on cumulative incidence function in analyzing time to cardiovascular diseasesCarotid intima-media thickness and plasma fibrinogen among subjects with metabolic syndrome: Isfahan cohort study, Iran.The cumulative incidence of conventional risk factors of cardiovascular disease and their population attributable risk in an Iranian population: The Isfahan Cohort Study.Evaluating factors associated with uncontrolled hypertension: Isfahan cohort study, Iran.Does the impact of metabolic syndrome on cardiovascular events vary by using different definitions?Psychological status and quality of life in relation to the metabolic syndrome: Isfahan Cohort Study.Validation of a simplified food frequency questionnaire for the assessment of dietary habits in Iranian adults: Isfahan Healthy Heart Program, Iran.The effect of supplementary calcium on blood pressure in healthy adult women aged 18-30 years in Tehran, Iran.Effect of self-care education on lifestyle modification, medication adherence and blood pressure in hypertensive adults: Randomized controlled clinical trialSynergistic effect of hypertension with diabetes mellitus and gender on severity of coronary atherosclerosis: Findings from Tehran Heart Center registry.Advanced method used for hypertension's risk factors stratification: support vector machines and gravitational search algorithm.The first Iranian recommendations on prevention, evaluation and management of high blood pressureDo Cardiometabolic Risk Factors Relative Risks Differ for the Occurrence of Ischemic Heart Disease and Stroke?Predictors of metabolic syndrome in the Iranian population: waist circumference, body mass index, or waist to hip ratio?Association of glutathione S-transferases M1 and T1 gene polymorphisms with the risk of metabolic syndrome in an Iranian populationIs prehypertension a risk factors for cardiovascular diseases among Iranian women?Predicting metabolic syndrome using decision tree and support vector machine methods.Is there any relationship between different phenotypes of metabolic syndrome and cardiovascular mortality rate?Determinants of incident prediabetes and type 2 diabetes in a 7-year cohort in a developing country: The Isfahan Cohort Study.Effect of soybean protein on blood pressure in postmenopausal women: a meta-analysis of randomized controlled trials.Pre-hypertension, pre-diabetes or both: which is best at predicting cardiovascular events in the long term?Usual Intake Distribution of Vitamins and Prevalence of Inadequacy in a Large Sample of Iranian At-Risk Population: Application of NCI Method.Mashhad stroke and heart atherosclerotic disorder (MASHAD) study: design, baseline characteristics and 10-year cardiovascular risk estimation.Dietary patterns and mortality from cardiovascular disease: Isfahan Cohort Study.Intake of legumes and the risk of cardiovascular disease: frailty modeling of a prospective cohort study in the Iranian middle-aged and older population.Predictive role of adiponectin and high-sensitivity C-reactive protein for prediction of cardiovascular event in an Iranian cohort Study: The Isfahan Cohort Study.Which Components of Metabolic Syndrome have a Greater Effect on Mortality, CVA and Myocardial Infarction, Hyperglycemia, High Blood Pressure or Both?PARS risk charts: A 10-year study of risk assessment for cardiovascular diseases in Eastern Mediterranean Region.Cardiovascular disease events and its predictors in women: Isfahan Cohort Study (ICS).Persian Registry Of cardioVascular diseasE (PROVE): Design and methodology.Design and implementation of a combined observational and interventional study: Trends of prevalence, awareness, treatment and control hypertension and the effect of expanded chronic care model on control, treatment and self-care.
P2860
Q33778040-60B10166-8778-4533-93E8-91F5DCBD29FBQ34609163-97CA8C1A-5611-474A-B0FF-4B92D30D7E48Q34659735-2F74A665-90E2-4BAF-AE69-F0F3AB16A17FQ35160615-D59FD99A-970D-41D1-8A66-C0B9B312B9E8Q35881266-56EB4985-5905-4FB8-A222-8B9838D8F134Q35998066-1C225CF1-A7A4-4F7C-A025-CC7AC5CA0DD7Q36055382-86D4F630-6500-4D36-AF19-665E1CE31655Q36085243-CD53BF12-75F4-4F7C-AF46-0411DCE1D053Q36206368-BD49A42A-8379-494C-AF8F-67FBA11BF732Q36535333-0C2DC1BB-0164-4E03-82C5-255993FA9D90Q36535355-382C86FF-FD41-4515-8EA0-4382A6223230Q36569409-F038B18E-0255-441C-8F72-7557CC0BEE06Q36577412-F627CBC2-735B-49A8-9BFC-1E67B520848FQ36748273-E4BA81ED-EE84-422E-823D-B1829BB5DC44Q36801273-2C52F54C-4F91-4FF4-B210-F3CDA2E8DFCEQ36973997-E14C801F-F971-447F-92CF-DCBD11E1A0DAQ37321571-BA9B45A2-BCA5-4EB7-B368-313F823E65B8Q37504631-85A4B045-0209-42E9-8FE1-AD4B8FE56A08Q39106961-9EBF43AE-A95A-4B48-B6B3-8BBDD0166325Q39413234-66EE880B-C858-4A3E-8DB2-8A3D4944BAD0Q39662159-C063AF4C-6F25-4538-B11F-B95227C996EDQ40270773-2D67C535-3F97-48D4-9D01-241E8931F397Q40277868-EAC9023A-B44F-4ED8-90EB-2C734EFC463FQ40414074-433E763D-2212-4821-8680-63CBCE909601Q40513296-A3B09001-80D9-4B64-A92D-8BC6B5327612Q41370105-0723E4EB-C46B-4EA6-9AC1-E0FDCEB32F57Q42280882-049103AB-EF85-489D-8D40-B3B4C6B4CF1FQ47133024-20AEE670-917C-4D6E-AFDE-A78CDD75A2DBQ47146731-128C0D65-30DF-4A70-863C-9043DC185ADCQ47711006-F513619A-9E76-4498-BADE-B3C0B26BBA49Q49478266-DDBFF64B-82D4-4571-846C-7B0160D01CAA
P2860
The Isfahan cohort study: rationale, methods and main findings.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
The Isfahan cohort study: rationale, methods and main findings.
@en
The Isfahan cohort study: rationale, methods and main findings.
@nl
type
label
The Isfahan cohort study: rationale, methods and main findings.
@en
The Isfahan cohort study: rationale, methods and main findings.
@nl
prefLabel
The Isfahan cohort study: rationale, methods and main findings.
@en
The Isfahan cohort study: rationale, methods and main findings.
@nl
P2093
P2860
P356
P1476
The Isfahan cohort study: rationale, methods and main findings.
@en
P2093
A R Sajjadieh
A Tavasoli
G N Thomas
N Mohammadifard
N Sarrafzadegan
S Oveisgharan
P2860
P2888
P304
P356
10.1038/JHH.2010.99
P577
2010-11-25T00:00:00Z
P5875
P6179
1001623552